Lars Fogh Iversen
Lars Fogh Iversen, PhD, is Senior Vice President and Head of Global Research Technologies at Novo Nordisk A/S. He is responsible for driving drug innovation at Novo Nordisk across all therapy areas (Diabetes, Obesity, NASH, Rare blood disorders, Rare endocrine disorders, Chronic Kidney and Cardiovascular Disease). This is achieved by discovering new molecules, designing new processes and engineering new formulations with the overall goal of bringing new innovative therapy treatments to patients.
Lars has been an employee of Novo Nordisk since 1997 and has served in various leadership roles since 2000. Lars has been heading up Global Research Technologies since its formation in 2018.
Lars Fogh Iversen holds a M.Sc in Pharmacy from the Royal Danish School of Pharmacy and a M.Sc in Human Biology from University of Copenhagen. Furthermore, Lars received a PhD in Protein Crystallography from University of York and University of Copenhagen. He has co-/authored 20+ peer-reviewed research papers and is an inventor on numerous international patent applications.
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.
To join Lars and the rest of the Lab of the Future community this October, register here.